fbpx
QQQ
+ 0.00
304.28
+ 0%
DIA
+ 0.00
300.01
+ 0%
SPY
+ 0.00
366.67
+ 0%
TLT
+ 0.00
157.51
+ 0%
GLD
-0.02
172.84
-0.01%

Amyris Denies 'Patent Infringement' Allegations On Heels Of $881M Lavvan Lawsuit

September 11, 2020 3:25 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Biotech firm Amyris Inc. (NASDAQ:AMRS) is clapping back at allegations made by Lavvan Inc. that it committed patent infringment.

"Amyris is disappointed that LAVVAN has chosen the public domain to articulate its position," Amyris CEO John Melo said in a statement Friday. "We will pursue our legal rights to the fullest extent possible, including a vigorous defense against any assertions made by LAVVAN."

In an $881 million lawsuit, New York-based Lavvan detailed how a $300-million deal it had set up with Amyris back in March 2019 had gone sour.

Amyris would provide Lavvan with R&D resources to develop, test and produce biosynthetic cannabinoids. Lavvan, which agreed to make payments with each milestone it reached, claims Amyris missued its intellectual property and misappropriated trade secrets. 

Lavvan filed the lawsuit in the Southern District of New York.

"LAVVAN owns exclusive rights to the intellectual property which Amyris is wrongfully using in connection with their development, testing and production of biosynthetic cannabinoids, including CBG," said Lavvan CEO Neil Closner in a prepared statement. 

Amyris used Lavvan's tech for a competitive advantage, Closner alleges.

"Amyris has falsely claimed that our agreement permits them to engage in these activities, but it plainly does not. We are very disappointed that we have had to take this step, but through a history of erratic and egregious conduct, Amyris has demonstrated a willful intention to undermine the agreement. This has left LAVVAN with no choice but to vigorously pursue all legal avenues available to protect its rights."

Amyris, which operates in the health and beauty markets, has set up similar agreements with other companies.

"Over the years, we have achieved in excess of $650 million in proceeds from these partnerships," Melo said. 

Courtesy image


Related Articles

Emerald Health Pharmaceuticals To Raise $17M Via New Reg A+ Round

Emerald Health Pharmaceuticals Inc. (EHP) is launching a new financing round under its Regulation A offering. The round will open on Monday, Dec. 7, and expire on Mar. 28, 2021, or upon raising roughly $17 million, which is the maximum amount to be raised, the Sand Diego biotech company said. read more

Gaby Buys Mankind Cannabis Dispensary For $36.5M, Confirms $8.5M Private Placement

Shares of GABY Inc. (OTCQB: GABLF) are trading up almost 6% on Thursday afternoon, after the cannabis company announced a merger with Mankind Dispensary, one of the first licensed dispensaries in California. read more

420 Investor: 'This Is The Most Excited I've Ever Been' In Cannabis

Alan Brochstein, author of 420 Investor and founding partner of New Cannabis Ventures, says the recent political momentum behind the cannabis legalization push in the US — and the resulting rebound in cannabis stocks since the U.S. election — has him feeling extremely optimistic about the industry's future. read more

Canadian Cannabis Stocks Are Becoming Less Desirable Investments, Data Suggests

Cannabis stocks have taken a hit since Election Day, Nov. 3. The latest Hifyre cannabis sales data out of Canada suggests some concerning trends in the market. The Numbers: Month-over-month, Canadian retail cannabis sales were up just 4% in October and down 3% in November, Hifyre estimates. read more

New Cannabis Products: A Hemp Spirit, A New Jane West Collab, CBD From Citrus Peels

As the cannabis market expands, it's hard to keep track of the many products that launch every week. Benzinga put together a short list of some of the most interesting new cannabis products. read more